Open AccessFinal evaluation of the results of the СТІКс study (concomitant Xavron stroke therapy)
Author(s) -
С.П. Московко,
Oleksii Kyrychenko,
Hannah Rudenko
Publication year - 2021
Publication title -
meždunarodnyj nevrologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2307-1419
pISSN - 2224-0713
DOI - 10.22141/2224-0713.17.5.2021.238519
Subject(s) - edaravone , medicine , concomitant , free radical scavenger , stroke (engine) , ischemic stroke , pathological , acute stroke , intensive care medicine , ischemia , oxidative stress , mechanical engineering , tissue plasminogen activator , engineering
Ischemic stroke remains a pressing problem today. Its pathogenesis consists of a sequential cascade of reactions in the brain, which, in addition to ischemia, are responsible for further damage to brain tissue and slow down the development of compensatory and regenerative mechanisms. Attempts to break the pathological cascade have been going on for decades. The first promising molecule that demonstrated the potential of a scavenger (cleaner, absorber) of excessive aggressive peroxides in preclinical studies was MCI-186, which is used in clinical practice under the name edaravone. The aim of the study the results of which are presented in this paper was to establish the clinical effects of edaravone (Xavron) as a concomitant therapy of acute ischemic stroke (СТІКс) in real clinical practice.